Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?

van der Wekken AJ, Kok K, Groen HJM.

J Thorac Dis. 2018 Jul;10(Suppl 18):S2130-S2132. doi: 10.21037/jtd.2018.06.45. No abstract available.


Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification.

Meedendorp AD, Ter Elst A, 't Hart NA, Groen HJM, Schuuring E, van der Wekken AJ.

Front Oncol. 2018 May 22;8:176. doi: 10.3389/fonc.2018.00176. eCollection 2018.


Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers.

Wei J, van der Wekken AJ, Saber A, Terpstra MM, Schuuring E, Timens W, Hiltermann TJN, Groen HJM, van den Berg A, Kok K.

Cancers (Basel). 2018 Jan 4;10(1). pii: E10. doi: 10.3390/cancers10010010.


Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.

van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM.

PLoS One. 2017 Aug 30;12(8):e0182885. doi: 10.1371/journal.pone.0182885. eCollection 2017.


[New biopsy at lung cancer progression: rational treatment of resistant lung cancer].

Hijmering-Kappelle LBM, van der Wekken AJ, Hiltermann TJN, Groen HJM.

Ned Tijdschr Geneeskd. 2017;161:D1229. Review. Dutch.


Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small-cell lung cancer patient.

Ferronika P, van den Bos H, Taudt A, Spierings DCJ, Saber A, Hiltermann TJN, Kok K, Porubsky D, van der Wekken AJ, Timens W, Foijer F, Colomé-Tatché M, Groen HJM, Lansdorp PM, van den Berg A.

Ann Oncol. 2017 Jul 1;28(7):1668-1670. doi: 10.1093/annonc/mdx182. No abstract available.


CT-guided percutaneous hookwire localization increases the efficacy and safety of VATS for pulmonary nodules.

Klinkenberg TJ, Dinjens L, Wolf RFE, van der Wekken AJ, van de Wauwer C, de Bock GH, Timens W, Mariani MA, Groen HJM.

J Surg Oncol. 2017 Jun;115(7):898-904. doi: 10.1002/jso.24589. Epub 2017 Feb 23.


Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer.

van der Wekken AJ, Pelgrim R, 't Hart N, Werner N, Mastik MF, Hendriks L, van der Heijden EHFM, Looijen-Salamon M, de Langen AJ, Staal-van den Brekel J, Riemersma S, van den Borne BE, Speel EJM, Dingemans AC, Hiltermann TJN, van den Berg A, Timens W, Schuuring E, Groen HJM.

Clin Cancer Res. 2017 Aug 1;23(15):4251-4258. doi: 10.1158/1078-0432.CCR-16-1631. Epub 2017 Feb 9.


Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.

Saber A, van der Wekken AJ, Kok K, Terpstra MM, Bosman LJ, Mastik MF, Timens W, Schuuring E, Hiltermann TJ, Groen HJ, van den Berg A.

PLoS One. 2016 Apr 5;11(4):e0153065. doi: 10.1371/journal.pone.0153065. eCollection 2016.


Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer.

Saber A, van der Wekken AJ, Kerner GS, van den Berge M, Timens W, Schuuring E, ter Elst A, van den Berg A, Hiltermann TJ, Groen HJ.

PLoS One. 2016 Mar 23;11(3):e0152317. doi: 10.1371/journal.pone.0152317. eCollection 2016.


Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature.

van der Wekken AJ, Saber A, Hiltermann TJ, Kok K, van den Berg A, Groen HJ.

Crit Rev Oncol Hematol. 2016 Apr;100:107-16. doi: 10.1016/j.critrevonc.2016.01.024. Epub 2016 Jan 25. Review.


Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.

Mellema WW, Masen-Poos L, Smit EF, Hendriks LE, Aerts JG, Termeer A, Goosens MJ, Smit HJ, van den Heuvel MM, van der Wekken AJ, Herder GJ, Krouwels FH, Stigt JA, van den Borne BE, Haitjema TJ, Staal-Van den Brekel AJ, van Heemst RC, Pouw E, Dingemans AM.

Lung Cancer. 2015 Nov;90(2):249-54. doi: 10.1016/j.lungcan.2015.09.012. Epub 2015 Sep 15.


Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.

Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, Heideman DA, Berk Y, Buijs EJ, Speel EJ, Krouwels FH, Smit HJ, Groen HJ, Dingemans AM, Smit EF.

Lung Cancer. 2015 Sep;89(3):255-61. doi: 10.1016/j.lungcan.2015.05.023. Epub 2015 Jun 6.


An instrument dedicated for modelling of pulmonary radiotherapy.

Niezink AG, Dollekamp NJ, Elzinga HJ, Borger D, Boer EJ, Ubbels JF, Woltman-van Iersel M, van der Leest AH, Beijert M, Groen HJ, Kraan J, Hiltermann TJ, van der Wekken AJ, van Putten JW, Rutgers SR, Pieterman RM, de Hosson SM, Roenhorst AW, Langendijk JA, Widder J.

Radiother Oncol. 2015 Apr;115(1):3-8. doi: 10.1016/j.radonc.2015.03.020. Epub 2015 Apr 9.


The value of proteomics in lung cancer.

van der Wekken AJ, Hiltermann TJ, Groen HJ.

Ann Transl Med. 2015 Mar;3(3):29. doi: 10.3978/j.issn.2305-5839.2015.01.10.


Moving forward with circulating tumor cells and lung cancer.

Hiltermann TJ, van der Wekken AJ, Groen HJ.

J Thorac Dis. 2012 Oct;4(5):440-1. doi: 10.3978/j.issn.2072-1439.2012.08.08. No abstract available.


A novel EGFR mutation in exon 19 showed stable disease after TKI treatment.

van der Wekken AJ, Stigt JA, A't Hart N.

J Thorac Oncol. 2012 Aug;7(8):e8. doi: 10.1097/JTO.0b013e31825ccae8. No abstract available.

Supplemental Content

Loading ...
Support Center